News

AstraZeneca Pharma India has appointed Praveen K Mittal, Director - Corporate Affairs, with effect from 06 July 2026

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales578.61480.48 20 2275.581716.29 33 OPM %10.5317.98 -11.5114.80 - PBDT64.82101.84 -36 286.03293.14 -2 PBT59.2284.15 -30 257.45253.15 2 NP44.8858.25 -23 187.52115.74 62 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Astrazeneca Pharma India announced that Jes�s Diaz-Ropero Esteso has resigned from the position of Non-Executive Director of AstraZeneca Pharma India and consequently from the Board Committee(s) on which he served, with immediate effect, due to a transition from current responsibilities. Powered by Capital Market - Live News